Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Double-blind Randomized Placebo-controlled Study of BFKB8488A in Japanese NAFLD Patients
jRCT2051210005Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing BFKB8488A arm with Placebo arm (2 arms). Primary endpoints: Safety and tolerability and Pharmacokinetics of BFKB8488A. Started Jun 2021; status: completed.
02
Drugs
fazpilodemab
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCT2051210005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210005.